# Breakout Ventures

> Breakout Ventures is a San Francisco venture capital firm founded in 2016 by Lindy Fishburne and Julia Moore. It backs early-stage, science-driven companies combining biology, chemistry and technology, with investments spanning health, industrial biotechnology and sustainability. Its third fund closed at $114 million in March 2026.

- **Founded:** 2016
- **Headquarters:** San Francisco, United States
- **Founders:** Lindy Fishburne (Co-founder and Managing Partner), Julia Moore (Co-founder and Managing Partner)
- **Products:** Early-stage venture investment, Founder and commercialization support, Breakout Fellowship
- **Notable:** Raised three announced funds totaling approximately US$286.5 million in commitments, using a rounded US$60 million Fund I figure., Fund II backed Surf Bio, acquired by Halozyme in December 2025; publicly announced terms were US$300 million upfront plus up to US$100 million in milestones., Portfolio company Cytovale received FDA 510(k) clearance for IntelliSep on December 20, 2022.

## Products & services

- **Early-stage venture investment** — Equity investment in science-driven startups, historically from seed through Series A; often acts as a lead investor.
- **Founder and commercialization support** — Support with business models, financing, technical commercialization and corporate or strategic connections.
- **Breakout Fellowship** — Two-year fellowship connecting PhD candidates and postdoctoral researchers to venture investing, diligence and commercialization; the 2023 announcement says the program began in 2015 under the broader Breakout ecosystem.

## Achievements

- Raised three announced funds totaling approximately US$286.5 million in commitments, using a rounded US$60 million Fund I figure.
- Fund II backed Surf Bio, acquired by Halozyme in December 2025; publicly announced terms were US$300 million upfront plus up to US$100 million in milestones.
- Portfolio company Cytovale received FDA 510(k) clearance for IntelliSep on December 20, 2022.
- Portfolio company Noetik announced a five-year GSK model-licensing collaboration in January 2026.

## Latest updates

- **2026-08** — Portfolio company Noetik announced achievement of the first near-term milestone in its GSK collaboration.
- **2026-03** — Closed US$114 million Fund III; the announcement described three initial seed investments, including Reach Industries and two then-stealth companies.
- **2026-01** — Halozyme publicly announced the Surf Bio acquisition completed in December 2025.

## Links

- Website: https://breakout.vc/
- LinkedIn: https://www.linkedin.com/company/breakout-ventures/
- Twitter/X: https://twitter.com/Breakout_Labs

---

Profile page: https://yespress.io/breakout-ventures
Published by YesPress — https://yespress.io
Last updated: 2026-10-27